+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hepatorenal Syndrome (CRC) - Epidemiology Forecast to 2030

  • ID: 5292779
  • Report
  • February 2021
  • Region: Global
  • 62 pages
  • DelveInsight
1 of 2
This ‘Hepatorenal syndrome (HRS)-Epidemiology Forecast - 2030’ report delivers an in-depth understanding of the Hepatorenal syndrome (HRS), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Hepatorenal syndrome (HRS) Disease Understanding

Hepatorenal syndrome (HRS) is a unique form of functional renal failure due to diminished renal blood flow, which occurs typically in histologically normal kidneys. It is a severe complication of advanced liver disease and characteristically affects patients with cirrhosis and ascites.

The term “Hepatorenal syndrome” was first used in 1939 to describe renal failure after biliary surgery or hepatic trauma. Later it was extended to other types of acute renal failure in liver diseases. In 1996, the International Ascites Club proposed a new definition and diagnostic criteria for HRS; since then, this term has been generally accepted for the functional renal failure that develops in patients with advanced cirrhosis.

HRS’s definition evolved with time, and the term became synonymous with severe organ dysfunction that involved both the liver and kidneys simultaneously. The International Club of Ascites has recently recommended a new definition, according to which HRS diagnosis relies on serum creatinine changes instead that on a fixed high value. The main change produced by adopting the new definition of HRS is removing a rigid very high cut-off value of sCr (2.5 mg/dL or 220 μmol/L) to start pharmacologic treatment. In this way, treatment can be administered early, and potentially better efficacy could be achieved.

The International Club of Ascites classified HRS into types 1 and 2 (HRS-1 and HRS-2). HRS-1 is characterized by a rapid deterioration of renal function that often occurs because of a precipitating event, while HRS-2 is a slowly progressive renal dysfunction that often occurs without an obvious precipitant. Clinically, HRS-1 is characterized by acute renal failure (ARF), while refractory ascites mainly characterize HRS-2. Recent changes in terminology have led to acute or Type I HRS being referred to as AKI-HRS and chronic or Type II HRS as chronic kidney disease (CKD)-HRS.

Hepatorenal syndrome (HRS) Epidemiology

The Hepatorenal syndrome (HRS) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Hepatorenal syndrome (HRS) epidemiology segmented as the Total Incident Cases of Hepatorenal Syndrome (HRS), Diagnosed Incident Cases of Hepatorenal syndrome (HRS), Type-specific cases of Hepatorenal syndrome (HRS). The report includes the Incident scenario of Hepatorenal syndrome (HRS) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Hepatorenal syndrome (HRS) Epidemiology

The epidemiology segment also provides the Hepatorenal syndrome (HRS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total Incident population of Hepatorenal syndrome (HRS) Associated in 7MM countries was estimated to be 282,616 cases in 2020 and expected to increase at a CAGR of 0.24% for the study period i.e. 2017-2030.
  • As per the estimates, Germany has the highest Incident population of Hepatorenal syndrome (HRS)
  • Among the EU5 countries, Germany had the highest Incident population of Hepatorenal syndrome (HRS). On the other hand, Italy had the lowest number of cases as 11,861 cases in 2020
Scope of the Report
  • Hepatorenal syndrome (HRS) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • Hepatorenal syndrome (HRS) Epidemiology Report and Model provide an overview of the risk factors and global trends of Hepatorenal syndrome (HRS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Hepatorenal syndrome (HRS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Hepatorenal syndrome (HRS)
  • The report provides the segmentation of the Hepatorenal syndrome (HRS) epidemiology by Incident Cases of Hepatorenal syndrome (HRS) in 7MM
  • The report provides the segmentation of the Hepatorenal syndrome (HRS) epidemiology by Etiology -specific Incident Cases of Hepatorenal syndrome (HRS) in 7MM
Report Highlights
  • 10-year Forecast of Hepatorenal syndrome (HRS) epidemiology
  • 7MM Coverage
  • Total Incident Cases of Hepatorenal syndrome (HRS)
  • Incident Cases according to segmentation: Type-specific Incidence of Hepatorenal syndrome (HRS)
KOL Views

We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate the secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM concerning the patient population about Hepatorenal syndrome (HRS)?
  • What are the key findings of Hepatorenal syndrome (HRS) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients with Hepatorenal syndrome (HRS) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2017-2030)?
  • What are the disease risk, burden, and unmet needs of Hepatorenal syndrome (HRS)?
  • What are the currently available treatments for Hepatorenal syndrome (HRS)?
Reasons to Buy

The Hepatorenal syndrome (HRS) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Hepatorenal syndrome (HRS) market
  • Quantify patient populations in the global Hepatorenal syndrome (HRS) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hepatorenal syndrome (HRS) therapeutics in each of the markets covered
  • Understand the magnitude of Hepatorenal syndrome (HRS) population by its Incidence cases
  • Understand the magnitude of Hepatorenal syndrome (HRS) population by its Types-specific cases
  • The Hepatorenal syndrome (HRS) epidemiology report and model was written and developed by Masters and PhD level epidemiologists
  • The Hepatorenal syndrome (HRS) Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period:
2017-2030

According to the National Organization for Rare Disorders (NORD), the exact incidence of Hepatorenal syndrome is unknown. It is estimated to occur in approximately 8-10% of individuals with Ascites and Cirrhosis.
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Hepatorenal Syndrome (HRS) Market Overview at a Glance
2.1. Market Share (%) Distribution of Hepatorenal Syndrome (HRS) in 2017
2.2. Market Share (%) Distribution of Hepatorenal Syndrome (HRS) in 2030

3. Executive Summary

4. Disease Background and Overview
4.1. Introduction
4.2. Symptoms
4.3. Etiology and Risk Factors
4.4. Pathophysiology
4.5. Precipitating Factors
4.6. Classification and Diagnosis Criteria of Hepatorenal Syndrome

5. Epidemiology and Patient Population
5.1. Key Findings

6. Country-wise Epidemiology of Hepatorenal Syndrome: 7MM

7. Assumptions and rationale
7.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in 7MM
7.2. The United States
7.2.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in the United States
7.2.2. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in the United States
7.2.3. Type-specific Incidence of Hepatorenal Syndrome (HRS) in the United States
7.3. EU5 Countries
7.3.1. Germany
7.3.2. Total Incident Cases of Hepatorenal Syndrome (HRS) in Germany
7.3.3. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Germany
7.3.4. Type-specific Incident of Hepatorenal Syndrome (HRS) in Germany
7.4. France
7.4.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in France
7.4.2. Diagnosed incidence of Hepatorenal Syndrome (HRS) in France
7.4.3. Type-specific Incidence of Hepatorenal Syndrome (HRS) in France
7.5. Italy
7.5.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in Italy
7.5.2. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Italy
7.5.3. Type-specific Incident of Hepatorenal Syndrome (HRS) in Italy
7.6. Spain
7.6.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in Spain
7.6.2. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Spain
7.6.3. Type-specific Incident of Hepatorenal Syndrome (HRS) in Spain
7.7. United Kingdom
7.7.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in the United Kingdom
7.7.2. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in the United Kingdom
7.7.3. Type-specific Incidence of Hepatorenal Syndrome (HRS) in the United Kingdom
7.7.4. Japan
7.7.5. Total Incident Cases of Hepatorenal Syndrome (HRS) in Japan
7.7.6. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Japan
7.7.7. Type-specific Incidence of Hepatorenal Syndrome (HRS) in Japan

8. Appendix
8.1. Report Methodology
8.2. Reference

9. Publisher Capabilities

10. Disclaimer

11. About the Publisher

List of Tables
Table 1: New classification of HRS subtypes.
Table 2: New diagnostic criteria for HRS-AKI
Table 3: Total Incident Cases of Hepatorenal Syndrome (HRS) in 7MM (2017-2030)
Table 4: Total Incident Cases of Hepatorenal Syndrome (HRS) in the United States (2017-2030)
Table 5: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in the United States (2017-2030)
Table 6: Type-specific Incidence of Hepatorenal Syndrome (HRS) in the US (2017-2030)
Table 7: Total Incident Cases of Hepatorenal Syndrome (HRS) in Germany (2017-2030)
Table 8: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Germany (2017-2030)
Table 9: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Germany (2017-2030)
Table 10: Total Incident Cases of Hepatorenal Syndrome (HRS) in France (2017-2030)
Table 11: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in France (2017-2030)
Table 12: Type-specific Incidence of Hepatorenal Syndrome (HRS) in France (2017-2030)
Table 13: Total Incident Cases of Hepatorenal Syndrome (HRS) in Italy (2017-2030)
Table 14: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Italy (2017-2030)
Table 15: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Italy (2017-2030)
Table 16: Total Incident Cases of Hepatorenal Syndrome (HRS) in Spain (2017-2030)
Table 17: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Spain (2017-2030)
Table 18: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Spain (2017-2030)
Table 19: Total Incident Cases of Hepatorenal Syndrome (HRS) in the United Kingdom (2017-2030)
Table 20: Diagnosed Cases of Hepatorenal Syndrome (HRS) in the United Kingdom (2017-2030)
Table 21: Type-specific Incidence of Hepatorenal Syndrome (HRS) in the UK (2017-2030)
Table 22: Total Incident Cases of Hepatorenal Syndrome (HRS) in Japan (2017-2030)
Table 23: Diagnosed incidence of Hepatorenal Syndrome (HRS) in Japan (2017-2030)
Table 24: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Japan (2017-2030)

List of Figures
Figure 1: Symptoms of HRS
Figure 2: New Pathophysiological hypothesis of acute decompensation and the development of organ dysfunction in patients with cirrhosis
Figure 3: Mechanisms of renal injury potentially involved in HRS-AKI in patients with cirrhosis
Figure 4: Role of a precipitating factor in HRS
Figure 5: Criteria for the diagnosis of AKI based on absolute or percent increase of serum creatinine-based on the time of initial presentation (T0)
Figure 6: Criteria for the diagnosis of HRS-NAKI based on the time of initial presentation (T0)
Figure 7: Total Incident Cases of Hepatorenal Syndrome (HRS) in 7MM (2017-2030)
Figure 8: Total Incident Cases of Hepatorenal Syndrome in the United States (2017-2030)
Figure 9: Diagnosed Incidence of Hepatorenal Syndrome in the United States (2017-2030)
Figure 10: Type-specific Diagnosed Incidence of Hepatorenal Syndrome (HRS) in the US (2017-2030)
Figure 11: Total Incident Cases of Hepatorenal Syndrome (HRS) in Germany (2017-2030)
Figure 12: Diagnosed incidence of Hepatorenal Syndrome (HRS) in Germany (2017-2030)
Figure 13: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Germany (2017-2030)
Figure 14: Total Incident Cases of Hepatorenal Syndrome (HRS) in France (2017-2030)
Figure 15: Diagnosed incidence of Hepatorenal Syndrome (HRS) in France (2017-2030)
Figure 16: Type-specific Incidence of Hepatorenal Syndrome (HRS) in France (2017-2030)
Figure 17: Total Incident Cases of Hepatorenal Syndrome (HRS) in Italy (2017-2030)
Figure 18: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Italy (2017-2030)
Figure 19: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Italy (2017-2030)
Figure 20: Total Incident Cases of Hepatorenal Syndrome (HRS) in Spain (2017-2030)
Figure 21: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Spain (2017-2030)
Figure 22: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Spain (2017-2030)
Figure 23: Total Incident Cases of Hepatorenal Syndrome in the UK (2017-2030)
Figure 24: Diagnosed Incidence of Hepatorenal Syndrome in the UK (2017-2030)
Figure 25: Type-specific Incidence of Hepatorenal Syndrome (HRS) in the UK (2017-2030)
Figure 26: Total Incident Cases of Hepatorenal Syndrome (HRS) in Japan (2017-2030)
Figure 27: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Japan (2017-2030)
Figure 28: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Japan (2017-2030)
Note: Product cover images may vary from those shown
Adroll
adroll